Questionnaires
DYSFUNCTION
There were no significant group differences, after correction, between the placebo and escitalopram groups on any of the baseline questionnaires. The full results are reported in Table When examining differences between the change scores on the questionnaires between baseline and cognitive visit, the escitalopram group had significantly lower scores on the Changes in Sexual Functioning (CSFQ-14) Questionnaire, corresponding to higher dysfunction on dimension 5 (Orgasm/Ejaculation (t (42.25) = 2.68, There were no group differences between the placebo and escitalopram groups on any of the follow-up questionnaires. The full results are reported in Table 